Panelists: A. Keith Stewart, MB, ChB, Mayo Clinic; Sagar Lonial, MD, FACP, Emory University School of Medicine; Thomas Martin, MD, UCSF Helen Diller Family; Edward A. Stadtmauer, MD, University of Pennsylvania; Ajai Chari, MD, Mount Sinai Hospital; Amrita Krishnan, MD, FACP, City of Hope Cancer Center Published: Tuesday, Aug 14, 2018 Continue Reading
When it comes to multiple myeloma, patients’ bone health can have major implications on their outcomes – even before they are diagnosed, according to recent research conducted by Ashley Rosko, M.D. Rosko, who is an assistant professor at The Ohio State University Comprehensive Cancer Center, and her team used the Women’s Health Initiative (WHI) to...Continue Reading
A collaborative project in the UK between researchers from the University of Oxford, the University of Exeter and Chiddenbrook Surgery, Crediton, could lead to GPs using simple blood tests to improve the early diagnosis of myeloma. The study investigated the best combination of blood tests that could be used to diagnose the rare cancer within...Continue Reading
A North Wales cancer patient has become the first in the world to take part in a new trial looking for a more effective treatment for myeloma. The study compares two different combinations of cancer medicines to see which helps control myeloma better in patients whose disease is no longer responding to treatment, or whose...Continue Reading
A multidisciplinary team of researchers from the National University of Singapore (NUS) has developed an artificial intelligence (AI) technology platform that could potentially change the way drug combinations are being designed, hence enabling doctors to determine the most effective drug combination for a patient quickly. Applying the platform towards drug resistant multiple myeloma, a type...Continue Reading
A group of “real-world” patients with relapsed or refractory multiple myeloma had high response rates and an overall survival (OS) of about 3 years when treated with bortezomib-based therapy, according to results of the electronic Velcade Observational Study (eVOBs). “While the benefits of bortezomib-based therapy have been exemplified in clinical trials, use of bortezomib for...Continue Reading
Chimeric antigen receptor (CAR) T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma (DLBCL), with research now exploring ways to shift these agents earlier in the treatment paradigm, according to a discussion at the 2nd Annual Live Medical Crossfire on Hematologic Malignancies. The quick arrival of...Continue Reading
Promising clinical trial data have highlighted advances in the treatment of mantle cell lymphoma (MCL), but an important next step is applying this progress to routine clinical practice, said Andre Goy, MD. These recent data have not only suggested that patients with MCL can expect a better quality of life with novel therapies, but also...Continue Reading
Researchers from the Icahn School of Medicine at Mount Sinai say they have developed a RNA and DNA sequencing platform that benefits late-stage and drug-resistant multiple myeloma patients by determining which drugs would work best for them. The team described its methodology (“Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach”) in JCO Precision...Continue Reading
Lenalidomide maintenance improved PFS and OS among patients with newly diagnosed multiple myeloma compared with other maintenance treatments, according to results from a network meta-analysis. “The continuous therapy approach has been evaluated extensively in patients with newly diagnosed multiple myeloma, across age groups and treatment strategies upfront, in several trials with different designs,” Francesca Gay, MD,...Continue Reading
